Harnessing genome-wide association studies to minimize adverse radiation-induced side effects.

ABSTRACT: Radiotherapy is used as definitive treatment in approximately two-thirds of all cancers. However, like any treatment, radiation has significant acute and long-term side effects including secondary malignancies. Even when similar radiation parameters are used, 5%-10% of patients will experience adverse radiation side effects. Genomic susceptibility is thought to be responsible for approximately 40% of the clinical variability observed. In the era of precision medicine, the link between genetic susceptibility and radiation-induced side effects is further strengthening. Genome-wide association studies (GWAS) have begun to identify single-nucleotide polymorphisms (SNPs) attributed to overall and tissue-specific toxicity following radiation for treatment of breast cancer, prostate cancer, and o

SUBMITTER: Benitez CM 

PROVIDER: S-EPMC7785837 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature